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Low- and middle-income countries (LMICs) bear a disproportionately high burden of the global 
morbidity and mortality caused by chronic respiratory diseases (CRDs) including asthma, chronic 
obstructive pulmonary disease, bronchiectasis and post-tuberculous lung disease. CRDs are strongly 
associated with poverty, infectious diseases, and other non-communicable diseases, and contribute 
to complex multi-morbidity, with significant consequences for the lives and livelihoods of those 
affected.  
 
The relevance of CRDs to health and socioeconomic wellbeing is expected to increase over time, as 
life expectancies rise and the competing risks of early childhood mortality and infectious diseases 
plateau. As such, the World Health Organization has identified the prevention and control of CRDs as 
an urgent development issue and essential to the achievement of the Sustainable Development Goals. 
In this review we focus on CRDs in low- and middle-income settings (LMICs). We discuss the early life 
origins of CRDs, challenges in prevention, diagnosis and management in LMICs, and pathways to 




Non communicable diseases (NCDs) are a major cause of morbidity and mortality, accounting for 
approximately 70% of global deaths, with the highest risks of dying from NCDs observed in low- and 
middle-income countries (LMICs).1 The United Nations’ Sustainable Development Goals (SDG) aim to 
reduce the risk of premature mortality from NCDs by one third by 2030.2 Chronic respiratory diseases 
(CRDs), such as asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis and post-
tuberculous (TB) lung disease are common and frequently neglected NCDs that span the life course. 
They are frequently associated with high levels of cost, morbidity and risk of mortality due to 
persistent symptoms, activity limitation, and intermittent exacerbations requiring acute care. They 
disproportionately affect the poor in all countries, but particularly in LMICs where resources for 
research, prevention and management are scarce.3  
 
This review focuses on CRDs in LMICs. Although we recognise that poverty and social deprivation are 
global issues, people living in LMICs face a particularly toxic combination of damaging early life and 
environmental exposures, challenging social and political contexts, and limited access to high-quality 
health services. We discuss the early life origins of CRDs in LMICs, and potential approaches to the 
prevention of disease. We address the clinical and health system challenges faced in the management 
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of established disease. We suggest strategies for research and clinical capacity strengthening, for both 
prevention and management, and propose pathways to solutions that would contribute to achieving 
international targets for health including reducing morbidity and premature mortality, and achieving 
Universal Health Coverage. 
  
 
EARLY LIFE ORIGINS OF CHRONIC RESPIRATORY DISEASE 
Evidence that has been acquired mainly in HICs indicates that the in utero, infant, child and adolescent 
environment is crucial for lung development, with pre-school lung function tracking and predicting 
early adult lung function, into at least the seventh decade of life.4,5 Although comparable data are 
lacking from LMICs, it is likely that the same holds true here.6 Common to both settings are detrimental 
in utero and early childhood exposures, which may disturb lung development such that individuals fail 
to reach an optimal peak in early adulthood, with increased risk of CRDs later in life. The increased 
prevalence and severity of many of these harmful early life exposures in LMICs may explain the lower 
lung volumes observed amongst asymptomatic non-smoking adults in many sub-Saharan African (sSA) 
settings, compared to age- and height- matched adults in HICs.7 Reduced forced expiratory volumes 
in 1-second (FEV1) and forced vital capacity (FVC) in early adulthood have been associated with 
cardiovascular and metabolic morbidity in both HICs and LMICs.5,8-10 Given the likely importance of in 
utero and early childhood exposures to adult lung health and wellbeing, and the high prevalence of 
these adverse exposures in LMICs, interventions to mitigate early life exposures may be crucial for the 
prevention of CRDs in LMICs.  
 
In-utero exposures 
Tobacco and air pollution: In utero exposure to tobacco smoking alters lung structure and function, 
and immune responses in the developing foetus.4 Data from the Drakenstein child health study in 
South Africa – one of the first birth cohorts in sSA –  showed that infants of the one third of mothers 
who smoked during pregnancy had lower tidal volumes and higher lung clearance indices at age 6-
weeks, compared to infants of non-smoking women, suggesting impaired lung and airway 
development.11 Similar outcomes have been seen in relation to other forms of air pollution exposure, 
including atmospheric pollution.12 
Social deprivation: Maternal stress, depression, adverse living conditions, and intimate partner and 
neighbourhood violence are issues faced by women around the world. In  LMICs, these challenges are 
often experienced on a background of structural inequality, marked gender divisions, and a lack of 
access to Universal Health Coverage, such that women are particularly vulnerable.13,14 Maternal 
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psychological distress is negatively associated with measures of neonatal health including weight for 
age and head circumference,13 and positively associated with ongoing respiratory morbidity in 
children.6,15,16 Maternal alcohol exposure during pregnancy adversely impacts lung function at 6-
weeks, but this effect disappears by one-year.6,11 Better maternal nutrition may protect against 
childhood wheeze.17  
HIV infection: The prevalence of HIV among women of child-bearing age is high in many LMICs but the 
introduction of ‘test and treat’ approaches to combination antiretroviral treatment (cART), 
strengthened provision of cART, and dedicated programmes to prevent maternal to child transmission 
have dramatically decreased rates of perinatal infection.18 Whilst HIV-exposed but uninfected infants 
may have reduced early lung function, by the age of two years impairment is seen only in those 
children whose mothers had poorly controlled HIV disease during pregnancy.19  
Premature birth:  Premature births occur in 10% of all live births globally, but 80% of these are in 
LMICs.20  Preterm birth is associated with increased respiratory symptoms, airway obstruction, 
abnormal lung structure, and poorer cardiovascular health in childhood and early adulthood.21 22 
 
Childhood exposures  
Acute lower respiratory infection: Early childhood bacterial and viral infections are common in LMICs 
and are a risk factor for ongoing respiratory illness. Respiratory syncytial virus (RSV), rhinovirus (RV), 
adenovirus and Influenza A are amongst the most common viral pathogens detected in children with 
acute lower respiratory tract illnesses (LRTIs) in LMICs.23,24 Wheezing illnesses associated with RV and 
RSV in early life are strong predictors of childhood asthma by 6-years of age,25 whilst adenovirus 
related LRTIs have been associated with subsequent obliterative bronchiolitis/bronchiectasis.26 
Pneumonia is a major cause of mortality in children with an estimated incidence of 0.2-0.3 
episodes/child year.27 Contrary to previous findings in HICs, LRTIs in early childhood in sSA have been 
shown to be an independent risk factor for reduced lung function by 1-year.11,28 However, 
pneumococcal conjugate vaccine (PCV) is still only available to approximately 50% of children globally 
despite having been introduced 2 decades ago.29  
Pulmonary tuberculosis: Children <15 years account for 11% of incident TB disease globally30 and 
paediatricians in LMICs routinely report a high burden of post-TB sequelae including bronchiectasis 
and lung destruction amongst those successfully completing treatment.31  
Chronic HIV infection: Large numbers of children previously infected with vertically-acquired HIV are 
now growing into adolescence.32 These long-term survivors experience a high burden of CRDs 
including bronchiectasis, bronchiolitis obliterans, and impaired lung function.31,32 Deficits are more 
severe in those with delayed diagnosis and late ART initiation.33   
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Nutrition: LMICs increasingly face a dual burden of maternal and childhood malnutrition,34 which 
results in foetal growth restriction, stunting, wasting, and isolated nutrient deficiencies, but also 
children who are overweight or obese.35,36 The limited available data suggest that in utero and early 
childhood starvation have adverse effects on lung development that persist into adult life. Childhood 
obesity is also thought to cause long term airway disease and has been associated with asthma in 
LMICs.37   
Air pollution: Both indoor and outdoor air exposures may be relevant to child lung health. The 
relationship between early childhood biomass fuel exposure and lung development is unclear: delayed 
introduction of clean burning stoves into Guatemalan households (child age 18-57 months vs. 
<6months) was associated with lower, but not significantly different, rates of lung growth,38 and data 
from a clean stoves intervention study in rural Malawi showed a small but statistically significant 
difference (0.2 z-scores) in the FVC of children from households who had previously been provided 
with a clean burning stove compared to those who had not.39 In HICs, reductions in outdoor air 
pollution over time have been associated with better lung function in children from serial birth 
cohorts.40 Diesel exposure has been associated with poor asthma outcomes, and this may be 
particularly relevant in LMICs where trucks may be poorly maintained, use unregulated fuel, and drive 
in close proximity to habitations.41-43 
 
Towards solutions 
Prevention of CRDs in LMICs will require attention to in utero and early childhood exposures, which 
determine the trajectory of lung development and health over the course of an individual’s lifespan.  
Many of these exposures are amenable to public health intervention and are rooted in poverty among 
mothers and children. Existing programmes for maternal care must be strengthened to protect the 
physical and mental health of women of childbearing age and mothers,  improve access to high-quality 
antenatal care, and support maternal education about childhood nutrition and vaccination. 
Programmes that support HIV-infected mothers to prevent perinatal transmission and provide early 
childhood HIV testing must be maintained. We suggest that programmes to support early child health 
should be strengthened and should include secure access to high quality nutrition and effective 
immunisation.  Given ongoing uncertainty about the impact of air pollution on lung development, we 
suggest that efforts to promote behaviour change in cooking and ventilation practices should 
continue, as a potentially low-cost strategy to improve child health.44  Political action including 
taxation and effective legislation to regulate advertising will likely be needed to minimise exposure to 
smoking and e-cigarettes, alcohol, and household and atmospheric air pollution.45 This may be 
particularly relevant in LMICs, given increasing marketing and interference with public health efforts 
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by tobacco, alcohol, food and beverage companies, and limited national regulatory frameworks.3 
Many of these health system and political interventions are broad in their scope, and stand to benefit 
health beyond CRDs. However, without them, it is likely that the substantial burden of CRDs in LMICs 




Asthma is the most common CRD globally, affecting 272.7 million people in 2017,46 with LMICs 
contributing 94.5% of global asthma-related deaths and 87.8% of global disability-adjusted life years 
(DALYs) (Figure 1).47 Morbidity and mortality from asthma is largely preventable.48   
 
Diagnosis 
The Global Initiative for Asthma (GINA) suggests a syndromic approach for asthma diagnosis in LMICs, 
but stresses the importance of measuring variability in airflow for confirmation, using peak flow 
monitoring or spirometry with reversibility testing.49 Access to these tools is limited in LMICs, such 
that diagnostic capacity is severely constrained.50 Asthma is frequently underdiagnosed in children 
and adults  in LMICs, and is often more severe when eventually identified.51,52 
  
Management 
Management of chronic disease requires the use of inhaled corticosteroid (ICS) to improve symptom 
control and reduce hospitalizations and mortality.53  GINA now recommend as-required use of inhalers 
combining ICS with the rapid-onset long-acting bronchodilator (LABA) formoterol for adolescents and 
adults at treatment steps 1 and 2.49,54  Data from large clinical trials demonstrate that this approach is 
equivalent or superior to use of regular ICS with as-needed short-acting ß2 agonists (SABA) for reducing 
the risk of severe exacerbations, and uses a much lower dose of ICS with no clinically important 
difference in symptom control, at least in young people over age 12 and adults.55-58 Likewise, in 
moderate-severe asthma, joint as-required use of maintenance and reliever therapy with combination 
ICS-formoterol reduces severe exacerbations compared with conventional regular ICS-LABA therapy 
with SABA reliever.59 For mild asthma, if combination ICS-bronchodilator preparations are not 
available or affordable, separate ICS may be used whenever a SABA is taken.  
However, despite these guidelines and although ICS are crucial to disease management, they are 
frequently under prescribed, unavailable, or unaffordable to people with asthma in LMICs, with over-
reliance on inhaled bronchodilators alone, or oral preparations of salbutamol, theophylline or 
prednisolone instead.60-63 Health system capacity for long term follow-up with titration of medication 
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for symptom control is limited, and patient and clinician understanding of the need for chronic 
treatment may be limited, with 52-76% loss to follow-up  seen within 1-year in pilot projects in China, 
Benin and Sudan.60-62  
 
Towards solutions 
There are global strategies for asthma care in LMICs that can be adapted for national use.49 
Implementation will require guidance and training for health care workers of multiple cadres to 
improve the clinical recognition of asthma, to promote the use of syndromic diagnosis, and to ensure 
appropriate prescription of effective preventer medication. There is a need for improved access to 
diagnostic tools (peak flow meters and spirometry) and training in their use. Similarly there is a need 
for access to affordable quality-assured asthma medicines listed on the WHO Essential Medicines list 
(Table 1). Education of both patients and providers will be required to ensure appropriate use of 
inhalers, with emphasis on the importance of ICS, and training in inhaler technique using spacers will 
be needed to optimise drug delivery in both children and adults. Health services with capacity for 
follow-up of patients with asthma are rare in LMIC, but essential for preventing over-reliance on 




Data on the global burden of COPD shows widespread variability in the prevalence, causes, clinical 
presentation and mortality between and within LMICs.64 This is primarily related to poor access to 
spirometry and limited epidemiological data, but is compounded by controversy in the definition of 
COPD – for example it is unclear whether fixed ratios and percent predicted cut-offs or lower limit of 
normal (LLN) boundaries should be used to identify abnormal results, which reference ranges to use 
for standardisation of measurements, and whether to consider all patients with fixed airflow limitation 
as having COPD.7 Notwithstanding this, community based data indicate that the prevalence of airway 
obstruction is between 6–20% in Latin America,65-67 and 5–24% in sSA.68-71 It is thought that LMICs 
contribute to 76.5% of the global COPD burden, 85% of global COPD deaths and 85% of the global 
COPD DALYs (Figure 1).47 Although tobacco smoking remains an important risk factor for airway 
obstruction in LMICs, between a third to a fifth of cases in LMICs are seen in never smokers, and a 






High rates of under-diagnosis and misdiagnosis are observed in LMICs,77,78 and data from national and 
international COPD surveys indicate that over 80% of COPD cases identified on spirometry are 
undiagnosed within routine clinical care.79 Unsurprisingly those with mild disease and without a 
history of exacerbations or admissions are less likely to have a diagnosis, but ethnicity, educational 
status, and lack of contact with health services also emerge as risk factors for under-diagnosis, 
suggesting broader socioeconomic determinants also.77-79 As noted above, limited access to 
spirometry for diagnosis globally is likely a key constraint.  
 
Management 
Standard management of smoking-related COPD includes non-pharmacological interventions 
(supported smoking cessation, pneumococcal and influenza vaccination, and pulmonary 
rehabilitation) and pharmacological treatment with inhaled therapies (short- and long-acting ß2 
agonists (SABA/LABA), short- and long-acting muscarinic antagonists (SAMA/LAMA), and ICS according 
to disease severity. These interventions are under-utilised in LMICs. In Latin America, population 
based surveys show that only half of smokers had physician counselling, a quarter received any 
respiratory medication, and access to influenza vaccination was limited.80,81 Results from the PUMA 
study showed that in primary care, the most widely used inhaled therapy was SABA, with long-acting 
bronchodilators and ICS relatively less used.82 There are no clinical trials that have investigated the 
appropriate pharmacotherapy for non-smoking-related COPD, including disease related to biomass 
pollutant exposure in LMICs, which may differ from that recommended for smoking-related COPD.  
 
Towards solutions 
There is an urgent need for the collection of better epidemiological data, accurate diagnosis, and 
appropriate clinical care for COPD in LMICs.83,84 Some of the  approaches required may be similar to 
those outlined for asthma above, including raising awareness amongst patients and providers, use of 
approved standardised guidelines for diagnosis and management, better access to spirometry, 
availability of inhaled therapies, education for both patients and health care providers, and access to 
long term follow-up. However, COPD in HICs has been associated with systemic sequelae including 
cardiovascular disease, malignancy, osteoporosis, depression and anxiety – there is a need to 
determine whether the same outcomes are seen in LMICs, and if the data are similar, programmes 
designed to address this multi-morbidity may be required.85 Broader access to cost-effective non-
pharmacological interventions including smoking cessation and pulmonary rehabilitation should be 
prioritised, and adapted for use in specific cultural contexts.86 Smoking remains the key driver of COPD 
globally, and ongoing efforts to translate lessons learnt in HICs about public health and policy 
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approaches to regulation across to LMICs, to reduce both direct and passive exposure, will require 
sustained support. Data on the risks, nature, outcomes and management of non-smoking related 




The reported population prevalence of non-cystic fibrosis bronchiectasis in HICs has increased in 
recent years to 566/100,000,87 with disease prevalence and severity associated with older age and 
female gender. Epidemiological data on bronchiectasis in LMICs is lacking,88 but  what data are 
available suggest that the prevalence, aetiology, and risk factors for bronchiectasis may be markedly 
different, with more post-infectious disease, an association with HIV infection, a higher burden of 




The diagnosis of bronchiectasis in LMICs is challenging. The clinical presentation is similar to that 
observed amongst patients in HICs, with chronic cough and sputum production in adults, and ‘failure 
to thrive’ in children, often associated with chronic, severe respiratory symptoms and recurrent 
infections. However, in many high TB incidence, low-resource settings, patients presenting with these 
symptoms are managed primarily as ‘TB-suspects’ and not evaluated for underlying CRDs. 
International guidelines for the diagnosis of bronchiectasis rely heavily on the use of CT imaging as the 
‘gold standard’ tool for diagnosis, but this tool is unavailable to the majority of those living in LMICs. 
There is little evidence to support the use of plain chest x-ray for the diagnosis of bronchiectasis, 
specifically, and few guidelines which support the use of chest x-ray for the investigation of chronic 
respiratory symptoms, in general.  
 
Management 
Management of bronchiectasis in HICs is increasingly individualised and focused on addressing 
‘treatable traits’ with the use of airway clearance tools, vaccination to prevent infection, appropriate 
treatment of infecting or colonising organisms, and early diagnosis and active management of 
intercurrent fungal and non-tuberculous mycobacterial (NTM) disease.91 These individualised 
approaches are not widely available in LMICs and, to our knowledge, there remain no guidelines for 





Improved investigation and management approaches for chronic productive cough amongst children 
and adults in LMICs are required. Standardised guidelines for decentralised care are needed, and 
should focus on feasible and scalable programmatic approaches.87 In high TB-burden settings, these 
guidelines must include appropriate investigation for active TB disease, but with consideration of 
underlying CRD, when TB is excluded. This will require better integration between TB-services and 
broader respiratory or medical services. Education of health workers about bronchiectasis as a cause 
of chronic productive cough, and accessible and affordable approaches to diagnosis in the absence of 
CT imaging are required to facilitate this. Patient-centred, low cost tools such as airway clearance have 
been shown to be acceptable and effective in children in South Africa and should be optimised for use 
in LMICs.92 An improved understanding of the microbiology of bronchiectasis in both children and 
adults is needed to inform population-level antibiotic recommendations.  
 
 
POST TB LUNG DISEASE (PTLD) 
Pulmonary tuberculosis (PTB) survivors, estimated at 58 million in this century alone,30 have two-to-
four-fold odds of persistently abnormal spirometry after TB-treatment completion (airway obstruction 
and low FVC patterns) compared to TB-naïve groups, with bronchiectasis, parenchymal cavitation and 
destruction, and fibrotic change widely seen on imaging.93-96 There is much heterogeneity in the 
prevalence, patterns and severity of residual pathology seen, but it is thought that bronchiectasis or 
abnormal spirometry are seen in over a third of PTB survivors.96-98 Those with post-TB lung disease 
(PTLD) may be at risk of long-term chronic respiratory symptoms, recurrent respiratory exacerbations, 
and accelerated lung function decline.97 TB-survivors are at increased risk of recurrent TB disease 
compared to TB-naïve populations, whether re-activation or re-infection,99 but chronic respiratory 
symptoms amongst those with PTLD also place them at high risk of empirical and un-necessary TB 
retreatment,100 with resultant treatment associated morbidity.101  Mortality in adult survivors of TB is 
almost three-times greater than that in the general population, but the direct association between 
PTLD and mortality is unclear.102 Of the 10 million annual cases of incident pTB, over 1 million occur in 
children,30 yet very little is known about the burden and impact of PTLD in this population. 
 
Diagnosis  
Abnormal spirometry or chest x-ray imaging can suggest a diagnosis of PTLD, but these tests are not 
routinely performed at successful TB treatment completion and may not be available at the point of 
care within decentralised TB-treatment programmes. The majority of those with residual PTLD are 
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therefore discharged without a diagnosis and without ongoing care.97 The diagnosis of recurrent TB 
amongst those with existing PTLD may be challenging: the specificity of nucleic acid amplification tests 
is reduced amongst TB-survivors, and the performance of screening tools including the WHO symptom 
screen and chest radiography in those with PTLD is unclear.103,104  
 
Management 
There has been little attention to long-term post-TB morbidity within International and National TB 
treatment guidelines to date, with no evidence-based guidelines available for the diagnosis and 
management of PTLD in LMICs.105,106 Existing approaches are based on models of COPD and 
bronchiectasis care, and include education about avoiding cannabis and smoking which are common 
co-exposures in TB populations, airway clearance exercises, vaccinations as per national guidelines, 
and use of inhaled bronchodilators for reversible airway obstruction.107 The use of ICS is not 
recommended given the associated increased risk of recurrent mycobacterial disease and other 
respiratory infections.108-110 Pulmonary rehabilitation may improve quality of life.111 Although sputum 
culture is the gold-standard tool for the diagnosis of recurrent TB disease and drug susceptibility 
testing in this group, culture is frequently not available in LMICs, and not feasible in young children. 
Further work is required to explore the performance of TB screening and diagnostic tools amongst 
PTB survivors and those with PTLD.  
 
Towards solutions 
TB treatment completion provides an opportunity to screen PTB survivors for residual lung pathology, 
with a view to ongoing follow-up and intervention. However, given resource constraints in LMICs, 
further evidence is required to inform decisions about how this should be done, which patients would 
benefit from ongoing follow-up, and the impact and cost-efficacy of clinical interventions for this 
group, before implementation of this approach. Clear evidence-based guidelines are also required for 
the diagnosis and management of those who are not identified at treatment completion, but re-
present with chronic respiratory symptoms, some years later. Integration of TB and CRD services will 
be required to optimise PTLD diagnosis and management,112 with improved approaches to the 
diagnosis of recurrent TB disease. We suggest that the broader cardiovascular, psychological and 
socioeconomic morbidities faced by TB-survivors should also be addressed within any packages of 
post-TB care.113  
 
 
HEALTH SYSTEMS STRENGTHENING 
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Strong health systems which are capable of providing effective and efficient services across the life-
course will be key to the prevention and management of CRDs and NCDs in LMICs, and must include 
the provision of comprehensive maternal care. Development of these systems will require attention 
to the six key ‘building blocks’ specified by the WHO: (i) service delivery, (ii) health workforce, (iii) 
health information systems, (iv) access to essential medicines and vaccines, (v) financing, and (vi) 
leadership/governance (Figure 2).114  
 
Several key weaknesses have been identified in these areas, with respect to respiratory care in LMICs. 
Health system surveillance data for respiratory diseases other than TB are few,115 limiting the capacity 
of countries to identify and plan for the health care needs of their populations. Robust indicators for 
the monitoring and evaluation of priority CRD programmes are lacking. National guidelines for the 
management of CRDs are also limited, and were identified in only 64% of countries in the seventh NCD 
country capacity survey 2019.116 Access to key diagnostic tools including spirometry and imaging is 
limited and in 2019 peak flow or spirometry were available in 45% of primary care facilities only, 
compared to 88% for blood glucose measurement.117 Access to preventative measures including 
vaccination, nutritional support, and smoking cessation services is limited.118 Crucially, the health 
workforce is poorly equipped to deliver respiratory care, with low numbers of respiratory 
specialists,119-122and most care delivered at the primary care level by nursing staff with limited 
training.123 Solutions to some of these challenges are explored below. 
 
Integrated delivery of CRD care 
Front-line primary-care staff in LMICs have a broad remit and are expected to provide preventative 
and curative care, for infectious and non-infectious diseases, to both children and adults. As such, it is 
crucial that CRD services are efficiently integrated within broader services and customised to local 
needs. Several approaches to integrated care have been developed for use in LMICs, to this end.124,125 
Early models, such as the WHO Practical Approach to Lung Disease (PAL), which was developed in part 
to improve case finding for TB, were focused only on respiratory diseases. These have been followed 
by tools with more comprehensive scope including the WHO PEN,126 WHO IMAI,127 and Package of 
Care Kit (PACK) for children, adolescents and adults.128 As an example, PACK includes a decision 
support tool for use across a range of clinical presentations and is available in both paper and 
electronic forms.129-132  It integrates local management guidelines and evidence, is regularly updated, 
and is supported by on-site, case-based, interactive training.133,134 Qualitative data confirm the 
effectiveness of this integrated care approach in improving CRD services, including the treatment of 




We suggest that respiratory and tuberculosis services should be closely linked in LMICs. Patients with 
acute and chronic respiratory disease frequently present with worsening respiratory symptoms and 
in high TB burden settings will usually require investigation for active TB disease. However, if TB 
investigations are negative it is important that alternative respiratory diagnoses are considered. 
Similarly, patients with PTLD at TB-treatment completion would benefit from clear and efficient 
integrated care pathways. 
 
Lastly, NCD programmes in LMICs should consider including palliative care support within their 
services. This is particularly important for CRDs which are frequently irreversible, progressive, and may 
be associated with distressing symptoms such as severe breathlessness. Such integration will require 
cultural awareness, education of staff and patients, development of symptom management 
approaches, and access to opioid medications.136  
 
Improving access to diagnostic tools 
Specific challenges to accessing diagnostic tools, including spirometry and imaging, at the primary care 
level include the funding of these services, and training in how to perform tests, maintain quality 
control, and accurately interpret results.137  Advances in the development of reliable and portable 
spirometry, ultrasound and chest x-ray equipment for community-based diagnosis may facilitate 
decentralisation, but services may prove more sustainable if accompanied by education and access to 
equipment maintenance services.138 It is likely that more sophisticated diagnostics such as CT imaging, 
complex lung function testing, and bronchoscopy will remain the purview of tertiary centres in LMICs, 
but these tools are of value in the training and retention of specialist physicians, and building research 
capacity, such that limited investment in their centralised use may be of some benefit.  
 
Improving access to treatment 
Although many key respiratory medications are included in the WHO essential medications list (Table 
1),139 access is limited: in 2019, ICS were generally available in 19% of low-income compared to 96% 
of high-income countries, and bronchodilators in 55% and 100% respectively.117 Even where available, 
these medications were frequently unaffordable to patients. Access to non-pharmacological 
interventions including pulmonary rehabilitation and smoking cessation services is also limited, 
despite these being among the most cost-effective interventions for CRDs, and relevant to the 
prevention and management of other NCDs including cardiovascular disease and cancer. Education 




Advocacy around access to these interventions is urgently needed. Key evidence gaps exist for the 
cost-effectiveness of newly recommended treatments for respiratory diseases, including ICS-
formoterol treatment as needed (and regularly and as needed) in asthma, and dual LAMA/LABA 
treatment in COPD, in LMICs. Quality pharmacoeconomic analysis should inform strategies for 
expanding the options and strategies promoted as Essential Drugs for respiratory diseases in LMICs, 
rather than assuming unaffordability. Strategies to facilitate the affordable delivery of quality-
controlled supplies of these medications will then be needed,140 and efforts to adapt and integrate 
non-pharmacological interventions into programs of care will be required. The development of a 
health workforce which can provide CRD services competently and compassionately is at the core of 
improving access.  
 
 
RESEARCH PRIORITIES & RESEARCH CAPACITY STRENGTHENING 
This review has highlighted several areas of uncertainty which we have formulated into research 
priorities for CRDs in LMICs (Table 2). However, these cannot be addressed without a thriving critical 
mass of LMIC investigators. The ‘Structured Operational Research Training Initiative’ (SORT-IT) course, 
and the American Thoracic Society/Pan African Thoracic Society ‘Methods in Epidemiological, Clinical 
and Operational Research’ (PATS-MECOR) course are examples of successful respiratory-focused 
programmes that provide training and networking opportunities for research-interested clinicians 
from LMICs, in order to build this capacity. Both SORT-IT and PATS-MECOR focus on clinical, 
epidemiological and operational research, or the “science of doing better”.141,142 Each also offers 
modules that cover concept development, grant and protocol writing, quality assured data capture 
and analysis, and manuscript writing. Participants are required to achieve various targets in order to 
progress, and strong, hands-on mentorship is offered throughout. Collectively, over 1000 participants 
from 90 countries have produced a large body of published literature that has contributed to changes 
in policy and practice in LMICs.141,143-146 Graduates have a strong track record of staying in research 




CRDs contribute substantially to the burden of disease in LMICs. Achieving the SDGs will require action 
to address this burden of disease through better prevention and care. Poverty reduction measures 
must be at the core of efforts for prevention, with a specific focus on improving maternal nutrition 
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and health, reducing exposure to airborne contaminants (tobacco smoke, household and atmospheric 
air pollution and occupational exposures), and improving the prevention and management of severe 
or untreated respiratory infections including tuberculosis, particularly in early life. Policy action 
directed at these causes of CRD will yield benefits in the short- and long-term. However, it is likely that 
a substantial burden of disease will remain, and evidence-based therapeutic strategies are also 
required to reduce ongoing morbidity and mortality amongst those with established CRDs. 
 
Improved data on the epidemiology of CRDs and their risk factors in LMICs are needed. There are 
many knowledge gaps, and extrapolating data from HICs may be to ignore the unique exposures, 
health system constraints, and social and political contexts which shape disease in LMICs. Renewed 
efforts are required to understand the pathophysiology of CRDs and patient outcomes in LMICs, and 
to develop approaches to diagnosis and management which are feasible, acceptable, and appropriate 
to local contexts. These should consider heterogeneity within, as well as between, countries. In a 
world where migration of peoples is increasing, the relevance of findings from LMICs to communities 
who have been forced or have chosen to relocate to other parts of the world should also be 
considered.152  
 
The Universal Health Coverage agenda offers an ideal opportunity to ensure the needs of those 
suffering from CRD are addressed through affordable and sustained access to appropriate and 
effective diagnostic evaluation, and pharmacological and non-pharmacological therapeutic 
interventions, and is relevant worldwide. CRD services would benefit from integration with broader 
TB and NCD care. The balance between programmatic approaches attempting to deliver simple 
standardised interventions, and personalised approaches seeking to target interventions more 
precisely, needs careful consideration and should be tailored to the local health care setting. However, 
in all contexts this will require resourcing and capacity building, with specific attention paid to the 
most peripheral levels of the healthcare system. This will be a challenge for many LMICs but highlights 
the importance of health system strengthening, capacity building and implementation research in 
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Table 1: Medications for CRD management, from WHO Model List of Essential Medicines134 
Category Drug [Route of administration] 
Respiratory medications – inhaled or nebulised 
 




Budesonide + Formoterol [inhaled] 
Ipratropium bromide [inhaled] 
Salbutamol [inhaled & nebulised] 
Tiotropium [inhaled] 
 




Medical gases Oxygen 
 
Pain and palliative care medications Opioid preparations (codeine, fentanyl, morphine) 
 
Antibiotics for respiratory infection 
 
To be adapted as per local guidelines 
 
Beta lactams: amoxicillin, amoxicillin + clavulanic acid, 
cefalexin, cefixime*, cefotaxime*, ceftriaxone* 
Tetracyclines: Doxycycline 
Macrolides: Azithromycin*, clarithromycin* 
Quinolones: Ciprofloxacin* 
Aminoglycosides: Amikacin, gentamicin 
Other: Sulfamethoxazole + trimethoprim, metronidazole, 
chloramphenicol 
 
Vaccines Childhood vaccines: pertussis, measles, diptheria, and 
H.influenzae type B 
Influenza vaccine (seasonal)  
Pneumococcal vaccine (conjugate & polysaccharide) 
*Antibiotics on the WHO ‘Watch’ list due to high resistance potential – for limited use, with guidance from local 








Table 2: Suggested research and clinical care priorities, for the delivery of CRD care in LMICs 
Remit Research need 




Development of birth cohorts in diverse settings in LMICs, to obtain prospective data on how 
genetic parameters, and in utero & early childhood exposures affect lung development 
Investigation of the long-term impact of nutrition, LRTIs and TB in children, and mechanisms for 
development of chronic respiratory disease 
Investigation of the origins, nature, and outcomes associated with low FVC phenomenon seen 
in LMICs 
New vaccine development to reduce childhood LRTI 
Asthma Investigation of the determinants of asthma-related morbidity and mortality in LMICs 
Development of feasible and scalable models for long-term asthma care, which include access 
to regular clinical review, and access to / education about the use of ICS medications 
Investigation of the pragmatic use of GINA-recommendations for as-required ICS-formoterol for 
steps 1 and 2 of asthma treatment, given challenges in making a definitive diagnosis of asthma 
and the potential overlap with other diagnoses including bronchiectasis and TB  
COPD Longitudinal data on patient outcomes associated with airway obstruction in smokers and non-
smokers in LMICs, and risk factors for morbidity and mortality 
Investigation of the efficacy of pharmacological and non-pharmacological therapies for non-
smoking related COPD in LMICs 
Bronchiectasis Development and validation of feasible and accessible tools for the diagnosis of bronchiectasis 
in LMICs (E.g. using questionnaires and CXR), against gold standard CT-based diagnostics 
Longitudinal data on patient outcomes associated with bronchiectasis in LMICs, with 
assessment of risk factors for morbidity and mortality  
Data on the microbiology of bronchiectasis in LMICs, including colonising organisms and those 
associated with exacerbations, in order to inform antibiotic guidelines 
Post-TB lung disease Investigation of host, pathogen, and environmental risk factors for PTLD 
Longitudinal data on patient outcomes associated with PTLD in LMICs, with assessment of risk 
factors for morbidity and mortality 
Investigation of the performance of TB diagnostic tools in those with PTLD being investigated 
for recurrent TB disease 
Determine the pathology underlying chronic respiratory symptoms in pTB-survivors re-
presenting to health services, after recurrent TB disease has been excluded 
CRD diagnosis Consensus guidelines for the use of spirometry performed in routine clinical practice in LMICs 
settings, including approaches to quality control, and use of reference ranges for 
standardisation 
Development and validation of simple screening tools for CRDs in decentralised care settings  
Development and validation of syndromic based diagnostic pathways, for individual CRDs 
including asthma, COPD, bronchiectasis and post-TB lung disease 
CRD management 
  
Investigation of pathogens causing respiratory exacerbations of CRDs in LMICs, to inform 
antibiotic guidelines and vaccine use 
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Optimisation of non-pharmacological CRD management tools for use in LMICs, including self-
management tools, pulmonary rehabilitation, airway clearance tools, and smoking cessation 
programmes 
Investigation of effect of ICS on risk of TB disease, in high TB incidence settings 
Inclusion of epidemiological data on CRD in LMICs into international registries and consensus 
statements, in order that LMIC needs are prioritised within global CRD research agendas 
Health systems 
  
Development of methods for programmatic data capture, to contribute data on the burden and 
nature of CRDs in LMICs, and to allow for local service planning and evaluation 
Development of models of integrated CRD care in LMICs, which are co-developed with patients 
and responsive to patient needs, integrated with TB and palliative care services, and integrated 
with the management of other NCDs (E.g. cardiovascular disease services), with tools for the 
evaluation of clinical impact and health system / patient costs 
 Development of key program Indicators for the planning, monitoring and evaluation of CRD 
interventions 
Training Development of a core curriculum for clinical respiratory training in LMICs, for multiple health 
professionals including nurses, physiotherapists, and non-specialist and specialist doctors 
Broader access to clinical and research-focused respiratory education and training platforms 







Figure 1: Distribution of the global burden of disease, deaths and DALYs from Chronic Respiratory Diseases (CRDs), COPD and Asthma, by World Bank defined 
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